QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer
QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer
Not yet recruiting · NCT07636226 · Registry updated 2026-06-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Not yet recruiting | Phase 2 / Phase 3 | 2026-06-09 | NCT07636226 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Sun Yat-sen University | 606 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||